Alchemab Therapeutics closed a Series A round (amount undisclosed) in Sep 2025. The company is based in London, UK. Investors in the round: DCVC Bio, Lightstone Ventures, Lilly and 3 others. Data as of 7 Aug 2026.
Amount undisclosed or unconverted.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
